Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:51 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study in Healthy Japanese Participants to Evaluate the Safety and Pharmacokinetics of Otilimab
NCT05304130 · GlaxoSmithKline · PHASE1 · withdrawn · last registry update 2023-01-26 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “This study was cancelled because of the limited efficacy demonstrated in the ContRAst phase III programme as a potential treatment for rheumatoid arthritis. GSK has decided not to progress with regulatory submissions” | – | Registry record, GlaxoSmithKline |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CSF2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-11-30Results posted on the registry: GlaxoSmithKline, GSK3196165 (Otilimab) + Tofacitinib (NCT03970837)
- 2023-11-30Also stopped (terminated): GlaxoSmithKline, GSK3196165 (Otilimab) + Tofacitinib (NCT03970837)
- 2023-10-25Results posted on the registry: GlaxoSmithKline, GSK3196165 (Otilimab) + Tofacitinib 5 mg (NCT03980483)
- 2023-07-17Results posted on the registry: GlaxoSmithKline, GSK3196165 (Otilimab) + Sarilumab (NCT04134728)
- 2023-06-05Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), Lenzilumab + Remdesivir (NCT04583969)
- 2023-05-06Results posted on the registry: I-Mab Biopharma US Limited, TJ003234 + Placebo (NCT04341116)
- 2022-03-09Results posted on the registry: GlaxoSmithKline, Otilimab + Placebo 1 (NCT04376684)
- 2022-03-08Results posted on the registry: Izana Bioscience Ltd., Placebo + Namilumab (NCT03622658)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision